Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$44.48 USD
-1.17 (-2.56%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $44.49 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Average Brokerage Rating
Current ABR | 1.11 |
ABR (Last week) | 1.11 |
# of Recs in ABR | 9 |
Average Target Price | $67.56 |
LT Growth Rate | 3.70% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.80 |
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.11 | 1.11 | 1.11 | 1.11 | 1.11 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/9/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Strong Buy | Strong Buy |
8/28/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
8/13/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
6/14/2024 | Wells Fargo Securities | Yanan Zhu | Strong Buy | Strong Buy |
6/12/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
6/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/12/2024 | Evercore Partners | Gavin Clark-Gartner | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.